Abstract：
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in children and adolescents, particularly those with obesity. NAFLD is considered a hepatic manifestation of the metabolic syndrome due to its close associations with abdominal obesity, insulin resistance, and atherogenic dyslipidemia. Experts have proposed an alternative terminology, metabolic dysfunction-associated fatty liver disease (MAFLD), to better reflect its pathophysiology. This study aimed to develop consensus statements and recommendations for pediatric MAFLD through collaboration among international experts.
METHODS: A group of 65 experts from 35 countries and six continents, including pediatricians, hepatologists, and endocrinologists, participated in a consensus development process. The process encompassed various aspects of pediatric MAFLD, including epidemiology, mechanisms, screening, and management.
RESULTS: In round 1, we received 65 surveys from 35 countries and analyzed these results, which informed us that 73.3% of respondents agreed with 20 draft statements while 23.8% agreed somewhat. The mean percentage of agreement or somewhat agreement increased to 80.85% and 15.75%, respectively, in round 2. The final statements covered a wide range of topics related to epidemiology, pathophysiology, and strategies for screening and managing pediatric MAFLD.
CONCLUSIONS: The consensus statements and recommendations developed by an international expert panel serve to optimize clinical outcomes and improve the quality of life for children and adolescents with MAFLD. These findings emphasize the need for standardized approaches in diagnosing and treating pediatric MAFLD.
BACKGROUND: This work was funded by the National Natural Science Foundation of China (82070588, 82370577), the National Key R&D Program of China (2023YFA1800801), National High Level Hospital Clinical Research Funding (2022-PUMCH-C-014), the Wuxi Taihu Talent Plan (DJTD202106), and the Medical Key Discipline Program of Wuxi Health Commission (ZDXK2021007).
METHODS: A group of 65 experts from 35 countries and six continents, including pediatricians, hepatologists, and endocrinologists, participated in a consensus development process. The process encompassed various aspects of pediatric MAFLD, including epidemiology, mechanisms, screening, and management.
RESULTS: In round 1, we received 65 surveys from 35 countries and analyzed these results, which informed us that 73.3% of respondents agreed with 20 draft statements while 23.8% agreed somewhat. The mean percentage of agreement or somewhat agreement increased to 80.85% and 15.75%, respectively, in round 2. The final statements covered a wide range of topics related to epidemiology, pathophysiology, and strategies for screening and managing pediatric MAFLD.
CONCLUSIONS: The consensus statements and recommendations developed by an international expert panel serve to optimize clinical outcomes and improve the quality of life for children and adolescents with MAFLD. These findings emphasize the need for standardized approaches in diagnosing and treating pediatric MAFLD.
BACKGROUND: This work was funded by the National Natural Science Foundation of China (82070588, 82370577), the National Key R&D Program of China (2023YFA1800801), National High Level Hospital Clinical Research Funding (2022-PUMCH-C-014), the Wuxi Taihu Talent Plan (DJTD202106), and the Medical Key Discipline Program of Wuxi Health Commission (ZDXK2021007).
摘要：
背景：非酒精性脂肪性肝病（NAFLD）在儿童和青少年中非常普遍，特别是那些肥胖的人。NAFLD被认为是代谢综合征的肝脏表现，因为它与腹部肥胖密切相关。胰岛素抵抗，和致动脉粥样硬化的血脂异常。专家们提出了一种替代术语，代谢功能障碍相关脂肪性肝病（MAFLD），以更好地反映其病理生理学。这项研究旨在通过国际专家之间的合作，为小儿MAFLD制定共识声明和建议。
方法：来自35个国家和六大洲的65名专家组成的小组，包括儿科医生,肝病学家,和内分泌学家，参与了共识发展进程。该过程涵盖儿科MAFLD的各个方面，包括流行病学,机制,筛选,和管理。
结果：在第1轮中，我们收到了来自35个国家的65项调查，并分析了这些结果，这告诉我们，73.3%的受访者同意20份声明草案，23.8%的受访者有点同意。协议或有些协议的平均百分比增加到80.85%和15.75%，分别,在第2轮。最后的陈述涵盖了与流行病学有关的广泛议题,病理生理学,以及筛查和管理儿科MAFLD的策略。
结论：国际专家小组制定的共识声明和建议有助于优化MAFLD儿童和青少年的临床结局并改善其生活质量。这些发现强调了诊断和治疗小儿MAFLD的标准化方法的必要性。
背景：这项工作得到了国家自然科学基金（82070588，82370577）的资助，国家重点研发计划(2023YFA1800801),国家高级医院临床研究资助（2022-PUMCH-C-014），无锡太湖人才计划(DJTD202106),和无锡市卫生健康委员会医学重点学科项目（ZDXK2021007）。
方法：来自35个国家和六大洲的65名专家组成的小组，包括儿科医生,肝病学家,和内分泌学家，参与了共识发展进程。该过程涵盖儿科MAFLD的各个方面，包括流行病学,机制,筛选,和管理。
结果：在第1轮中，我们收到了来自35个国家的65项调查，并分析了这些结果，这告诉我们，73.3%的受访者同意20份声明草案，23.8%的受访者有点同意。协议或有些协议的平均百分比增加到80.85%和15.75%，分别,在第2轮。最后的陈述涵盖了与流行病学有关的广泛议题,病理生理学,以及筛查和管理儿科MAFLD的策略。
结论：国际专家小组制定的共识声明和建议有助于优化MAFLD儿童和青少年的临床结局并改善其生活质量。这些发现强调了诊断和治疗小儿MAFLD的标准化方法的必要性。
背景：这项工作得到了国家自然科学基金（82070588，82370577）的资助，国家重点研发计划(2023YFA1800801),国家高级医院临床研究资助（2022-PUMCH-C-014），无锡太湖人才计划(DJTD202106),和无锡市卫生健康委员会医学重点学科项目（ZDXK2021007）。
